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ABSTRACT
Purpose Tryptophan’s (Trp) unique hydrophobic and struc-
tural properties make it an important antigen binding motif
when positioned in complementarity-determining regions
(CDRs) of monoclonal antibodies (mAbs). Oxidation of Trp
residues within the CDR can deleteriously impact antigen
binding, particularly if the CDR conformation is altered.
The goal of this study was to evaluate the conformational
and functional impact of Trp oxidation for twomAb subtypes,
which is essential in determining the structure-function rela-
tionship and establishing appropriate analytical control strat-
egies during protein therapeutics development.
Methods Selective Trp oxidation was induced by 2,2′-
Azobis(2-amidinopropane) dihydrochloride (AAPH) treat-
ment in the presence of free methionine (Met). The native
and chemically oxidized mAbs were characterized by
hydrogen-deuterium exchange mass spectrometry (HDX-
MS) for conformational changes and surface plasmon reso-
nance (SPR) for antigen-antibody binding.
Results Treatment of mAbs with AAPH selectively oxidized
solvent accessible Trp residues. Oxidation of Trp within or in
proximity of CDRs increased conformational flexibility in var-
iable domains and disrupted antigen binding.
Conclusions Trp oxidation in CDRs can adversely impact
mAbs’ conformation and antigen binding. Trp oxidation
should be carefully evaluated as part of critical quality attri-
bute assessments. Oxidation susceptible Trp should be closely
monitored during process development for mAbs to establish
appropriate analytical control for manufacturing of drug sub-
stance and drug product.
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INTRODUCTION
Monoclonal antibodies (mAbs) are a major class of protein
therapeutics in drug development pipelines and in the bio-
pharmaceutical drug market. To date, more than 60 mAbs
have been approved for treating diseases in several therapeu-
tic areas in the US (1). Currently, there are more than 50
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mAbs in late-stage clinical studies and many more in early
stages of development (2,3). One of the most valuable attri-
butes of a therapeutic mAb is rooted in the selective binding to
the antigen with high affinity via interaction of complementa-
ry determining regions (CDRs), which conveys sub-
nanomolar potency (4,5).
Similar to other protein therapeutics, mAbs are susceptible
to chemical and physical degradation during manufacture and
storage (6,7). Impact on higher-order structure and biological
function resulting from oxidation, isomerization, deamidation,
and aggregation has been widely studied and reported (8–12).
Depending on the location and extent of degradation, the safe-
ty, efficacy, and stability profiles could be altered.
A common chemical degradation pathway of protein ther-
apeutics is oxidation. Oxidation can be induced by light ex-
posure, thermal stress, or impurities such as metal ions and
peroxides (13). Among all amino acid residues in mAbs,
Methionine (Met) is the most susceptible residue to oxidation.
The impact of Met oxidation on the structure-function rela-
tionship of mAbs has been studied extensively (14–18).
Oxidation of other residues in proteins such as tryptophan
(Trp), cysteine, phenylalanine, tyrosine, and histidine have
also been reported (19–21). Aggregation, fragmentation, and
loss of binding activity as a result of oxidation of these residues
in mAbs have been reported while few have studied the im-
pact on higher-order structure (22–26).
Trp residues are commonly found in CDRs due to their
structural features and hydrophobic properties that confer
niche recognition points that facilitate strong and specific
binding between mAbs and their respective antigens.
However, Trp in CDRs may be more susceptible to oxidation
because of the relatively flexible and solvent accessible nature
of CDR loops (27–29). Conserved Trp residues in the con-
stant regions of mAbs are less solvent accessible, and hence less
susceptible to oxidation as they are buried within the 3-D
protein structure. Similar to exposed Met residues the expo-
sure to radicals generated frommetal, light, and thermal stress
during mAb manufacture and storage increases the risk of
exposed Trp oxidation (13,19). The mechanism of oxidation
in relation to type of exposure directly influences the degree of
oxidation risk. For example, exposed Met preferentially oxi-
dizes in relation to exposed Trp under hydrogen peroxide
exposure. In contrast, studies have demonstrated the prefer-
ential oxidation of Trp over Met under oxidizing conditions
(25,26,30). Under oxidizing conditions, Trp can form various
oxidation products including N-formylkynuernine (NFK),
kynurenine (Kyn), hydroxytryptophan (OH-Trp), and 3-
hydroxykynuerinine (3-OH-Kyn) (Fig. S1), increasing the
complexity of analytical characterization (31). The hydro-
phobic nature of a Trp side chain is drastically changed
once oxidized (32). Such changes can lead to undesirable
changes of mAb attributes. Previously, it has been shown
that oxidation of Trp residues in CDRs of mAbs can
impact antigen-antibody binding activity (25,26). This is
intuitive based on the increased polar nature and potential
for hydrogen bonding for oxidized Trp residues. To date
studies on Trp oxidation in CDRs have been limited to
bioactivity and stability studies (13,23,25,26). A detailed
understanding of the impact on the structure-function re-
lationship in the context of the local and overall confor-
mation of mAbs is still lacking. This knowledge is critical
for identifying the critical quality attributes of mAbs cur-
rently in development in order to establish appropriate
analytical control strategies for production and shelf life.
It is also invaluable to future drug candidate screening and
molecular design.
Hydrogen-deuterium exchange mass spectrometry (HDX-
MS) is a powerful technique for characterizing local and glob-
al protein conformations in solution (33,34). Today the appli-
cation of HDX-MS in development of biopharmaceuticals
has substantially grown as the technique becomes more auto-
mated, powerful, and routine to use (35). HDX-MS has been
widely used for the characterization of higher-order structure
of mAbs (36,37). Multiple studies have been reported using
HDX-MS to monitor the conformational impact of chemical
and physical modifications (8,12,17,38). Others have used
HDX-MS to understand the impact of chemical modifications
on biological functions through conformational changes
(9,18). HDX-MS results have revealed structural changes re-
sponsible for variation in function.
In this study we used HDX-MS to provide insight on the
conformational impact of Trp oxidation in two mAbs of IgG1
and IgG4 subtypes. As a widely used technique for character-
izing antibody-antigen binding activities, surface plasmon reso-
nance (SPR) was used in addition to HDX-MS to gain a better
understanding of the conformational impact of Trp oxidation
on changes in function. To the best of our knowledge, this is the
first report of using HDX-MS to study the conformational im-
pact of Trp oxidation in the CDRs of mAbs.
However, it is challenging to study the structural and func-
tional impact induced by Trp oxidation alone, since general
stress conditions including UV light exposure, thermal stress,
and oxidative agent exposure can induce Trp oxidation but
also induce other modifications, such as aggregation, frag-
mentation, or methionine oxidation (39–41). To understand
the structure-function impact of Trp oxidation in the CDRs,
Trp residues need to be selectively oxidized to a significant
extent without other major chemical/physical degradation.
To achieve selective oxidation of susceptible Trp residues on
mAbs, we used the approach of AAPH treatment in the pres-
ence of free Met (30). The oxidative mechanism of AAPH
mimics that of radicals formed during irradiation and metal
exposure (20,42). AAPH in combination with free Met mini-
mizes Met oxidation and physical degradations while oxidiz-
ing susceptible Trp significantly under mild conditions and in
a short timeframe.
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With this approach, we selectively oxidized susceptible Trp
to high levels on an IgG1 mAb with one susceptible Trp res-
idue in the CDR, and on an IgG4 mAb with two susceptible
Trp residues in the CDRs and one in the non-CDR of the
variable domain. SPR analysis of the Trp oxidized material
versus the reference material revealed that Trp oxidation in the
CDR disrupted antigen binding for bothmAbs, while only the
localized regions exhibited increased flexibility as evident by
HDX-MS analysis, indicating that the disruption of local
structure contributed to decreased antigen binding. This study
provides a general approach for exclusively evaluating the
structure-function relationship between Trp oxidation in
CDRs and its conformational impact on binding activities




The IgG1 mAb (mAb1) and IgG4 mAb (mAb4) were
produced in Bristol-Myers Squibb Company. They were
expressed in Chinese hamster ovary (CHO) cells and
purified by standard chromatographic steps. Both
mAbs were frozen and stored at −80°C in formulation
buffer. LC-MS grade water was purchased from
Honeywell (Plainview, NY). LC-MS grade acetonitrile
was purchased from J.T. Baker (Center Valley, PA).
8 M Guanidine-HCl, premium grade TCEP-HCl, and
LC-MS grade formic acid were purchased from Thermo
Scientific Pierce (Grand Island, NY). Sequencing grade
trypsin was purchased from Promega (Madison, WI).
Human Fab capture kit, CM5 Sensor Chip, HBS-EP+
running buffer and amine coupling kit was purchased
from GE Healthcare Life Sciences (Piscataway, NJ). All
other reagents were purchased from Sigma-Aldrich (St.
Louis, MO) unless otherwise specified.
Oxidized Sample Preparation
To selectively oxidize Trp residues, 2,2-azobis(2-
amidinoporpane) dihydrochloride (AAPH) and L-
methionine were directly dissolved in each mAb solution to
achieve final concentrations of 25 mg/mL (AAPH), 33 mg/
mL (L-methionine), and 15 mg/mL (mAb). Samples were
incubated at room temperature protected from light.
Oxidation reaction was stopped by buffer exchange with for-
mulation buffer on an illustra NAP-5 column (GEHealthcare,
Piscataway, NJ) and samples were stored at −80°C before
being analyzed.
Oxidized Sample Characterization
Tryptic peptide mapping with tandem mass spectrometry
(MS/MS) was used to identify and quantify oxidation.
Reference and oxidized samples were denatured, reduced,
alkylated, and digested then separated in reversed phase liquid
chromatography on a UPLC BEH C18 2.1 × 100 mm col-
umn (Waters, Milford, MA) with an Acquity UPLC H-Class
system (Waters) and detected by a Q Exactive Plus mass spec-
trometer (Thermo Scientific, San Jose, CA). MS andMS/MS
spectra were analyzed by Xcalibur (Thermo Scientific) to
identify and quantify oxidation levels of tryptic peptides.
Size exclusion chromatography (SEC) was used to identify
and quantify soluble aggregates from AAPH treatment.
Reference and oxidized samples were separated on a
TSKgel G3000SWxl 7.8 mm × 30 cm column (TOSOH
Biosciences, King of Prussia, PA) on an Acquity UPLC H-
Class system (Waters) with photodiode array detection at
220 nm. Absorbance traces were analyzed by Empower
(Waters) to identify and quantify soluble aggregates.
SEC Fractionation
SEC fractionation was used to separate and collect oxidized
monomer from samples containing significant soluble aggre-
gates. Aggregates and monomer species were separated on a
TSKgel G3000SW 21.5 mm × 30 cm column (TOSOH
Biosciences) and collected on an AKTA Avant 25 (GE
Healthcare) fraction collector. Monomer fractions were com-
bined, concentrated, and buffer exchanged with formulation
buffer using an Amicon Ultra-15 centrifugal filter with a
30 kDa MWCO (EMD Millipore, Billerica, MA). Oxidized
monomer sample was stored at−80°C before being analyzed.
HDX-MS Protocol
HDX-MS experiments were performed on an HDXmanager
system with automatic sample handling, online digestion, and
separation (Waters). Non-deuterated samples were prepared
by diluting 3 μL (5 mg/mL) of each mAb sample (mAb1,
oxidized mAb1, mAb4, and oxidized mAb4) into 57 μL of
aqueous buffer (5 mM K2HPO4, 5 mM KH2PO4, in H2O,
pH 7.0). Labeling with deuterium was performed by diluting
3 μL of each mAb sample into 57 μL of deuterated buffer
(5 mM K2HPO4, 5 mM KH2PO4, in D2O, pD 7.0). HDX
reactions were maintained at 20°C and allowed to react for
20 s, 100 s, 500 s, 2500 s, and 12,500 s. The exchange reaction
was stopped by adding 1:1 (v/v) precooled (1°C) quench buffer
(200 mM potassium phosphate, 4 M guanidine-HCl, 0.5 M
TCEP-HCl, pH 2.5). A total of 75 μL of the quenched HDX
reaction sample was injected into the HDX system and passed
over a Poroszyme immobilized pepsin 2.1 mm× 30 mm col-
umn (Thermo Scientific) at 75 μL/min. The resulting peptic
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peptides were captured in HPLC mobile phase on a
VanGuard C18 trapping 2.1 mm× 5 mm column (Waters)
and desalted for 4 mins at 75 μL/min of H2O containing
0.1% formic acid. Peptides were then separated on a BEH
C18 1.0 mm× 50 mm column (Waters) with an 8 min linear
gradient of acetonitrile containing 0.1% formic acid increas-
ing from 8 to 40%. Protein digestion for both non-deuterated
and deuterated samples was carried out at 20°C; peptide cap-
ture and separation were carried out at 0°C. MS detection
was immediately performed after HPLC separation on a
Xevo G2-XS QTof mass spectrometer (Waters) running in
ESI-positive mode. Each experiment was carried out in
triplicate.
HDX-MS Data Analysis
Peptic peptides were identified based on HPLC separa-
tion of non-deuterated protein digest using MSE. MSE
data was analyzed using ProteinLynx global server 3.0
(Waters). Identified peptides were imported with three
parallel non-deuterated experiments into Dynamx 3.0
(Waters). Peptides with sufficient signal intensity and
confidence were pooled and used for HDX analysis.
Deuterium uptake level (#D) for each peptide at each
exchange time point was calculated using Dynamx 3.0
to generate uptake curves for each sample. Data obtain-
ed was used to make HDX difference charts in which
deuterium labeling for each peptide between the refer-
ence and oxidized states was compared.
SPR
mAbs were captured with anti-Fab antibody that was
immobilized (amine coupled) to a CM5 chip. Respective an-
tigen was flowed across two flow cells at concentrations rang-
ing from 0 to 40 nM with a reference subtracted flow cell
treated identically but without the mAb, the 0 nM injection
was used as a second subtraction resulting in the data being
double-reference subtracted. Antigen binding was measured
by a Biacore T200 instrument (GE Healthcare Life Sciences).
Data was analyzed by comparing antibody-antigen associa-
tion and dissociation kinetics between reference and oxidized
mAbs for mAb1 and mAb4 using Biacore T200 Evaluation
Software (GE Healthcare Life Sciences).
RESULTS AND DISCUSSION
Selective Trp Oxidation of mAb1 and mAb4 Using
AAPH
Both mAbs studied in this report have multiple residues
that are susceptible to oxidation. mAb1 contains one
Trp in CDR2 of heavy chain (HC) (Trp1), one Met
in CDR3 of HC (Met1), and three conserved Met in
fragment crystallizable (Fc) region (Met2–4) that are sus-
ceptible to oxidation. mAb4 contains one Trp in CDR3
of HC (Trp1), one Trp in variable domain of HC
(Trp2), one Trp in CDR3 of light chain (LC) (Trp3),
and three conserved Met in Fc region (Met1–3) that are
susceptible to oxidation. Samples containing high levels
of Trp oxidation and minimal levels of Met oxidation
are essential to the study of Trp oxidation impact on
the structure-function relationship using HDX-MS and
SPR.
In this report, susceptible Trp residues of the two
mAbs were selectively oxidized by AAPH in the pres-
ence of excess free Met. Five days of incubation for
mAb1 yielded the following oxidation levels: 86.7%
Trp1, 14.5% Met1, 3.0% Met2, 1.2% Met3, and
0.4% Met4 (Table I). Similarly, twenty days of incuba-
tion for mAb4 yielded the following oxidation levels:
99.9% Trp1, 85.9% Trp2, 99.8% Trp3, 8.3% Met1,
1.8% Met2, and 5.8% Met3 (Table II). The most abun-
dant Trp oxidation product observed for all oxidized
Trp is NFK which has a mass shift of +32 Da relative
to the native form (Fig. S1). Other modifications such as
deamidation, tyrosine cross-linking, histidine oxidation,
and shuffled disulfide bonds were carefully monitored
in the oxidized mAb1 and mAb4 samples via the tryptic
peptide mapping analysis. No significant modification
levels were observed (data not shown). While high levels
of oxidation at susceptible Trp residues were achieved
for both mAbs, low level of Met oxidation was main-
tained (<15%). This data demonstrates AAPH with ex-
cess free Met incubation is a valid approach to selec-
tively oxidize susceptible Trp residues. A previous report
by Folzer et al. using the same approach shows similar
success of selective oxidation of Trp residues on an
IgG1 mAb (37.6% and 82.1%) while maintaining low
level of Met oxidation (<11%) (30). The published re-
sults and our experimental data support the feasibility
and reliability of AAPH treatment in the presence of
excess free Met for Trp oxidation related studies.
However, it has been reported that some mAb oxidation
events are associated with increased amount of aggregation.
For example Liu at al. showed increased soluble aggregate
formation as a function of methionine oxidation in an isolated
IgG1 mAb Fc, and Hensel et al. made a similar observation
with methionine and tryptophan oxidation of an IgG1 mAb
(14,25). In our study, the oxidized mAb1 and mAb4 were
shown to contain <1% and 38% soluble aggregates by SEC
analysis, respectively (Fig. 1a and b). To eliminate interference
from soluble aggregates, fractionation by SEC was used to
reduce the amount of aggregates in mAb4 to less than 4%
(Fig. 1c).
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HDX-MS Results Reveal the Conformational Impact
of Trp Oxidation
HDX-MS was performed to characterize the conformational
impact of Trp oxidation on mAb1 and mAb4, in which
changes in conformation across full length mAbs due to Trp
oxidation were measured. Changes could be resolved at the
peptide level (5–20 residues). The number of peptides mea-
sured byHDX-MS reached 143 peptides (86% total sequence
coverage, see Fig. S2) for mAb1 and 140 peptides (88% total
sequence coverage, see Fig. S3) for mAb4. These peptides
were identified in both the reference and oxidized samples
(n= 3 for each sample). Peptides that were identified only in
the reference sample account for most of the areas of missing
coverage for both mAbs. Differences between reference and
oxidized samples in deuterium uptake highlight the regions of
structural perturbation, at peptide level, due to Trp oxidation.
Overall, two regions (HC: 23–36 and 50–68) of mAb1
show significantly increased deuterium uptake in oxidized
sample compared to the reference (Fig. 2a). Both regions are
within the VH domain containing oxidized Trp1. The deute-
rium uptake curves for overlapping peptides in these two re-
gions show faster deuterium exchange for oxidizedmAb1 (Fig.
2b). No other domains of mAb1 showed a significant differ-
ence in deuterium uptake. For example, in Fig. 2b, peptide
249–259 of the CH2 domain shows similar deuterium uptake
profile for reference and oxidized mAb1.
For mAb4, five regions (HC: 11–33, 48–78 and 110–123;
LC: 1–11 and 47–70) of mAb4 show significantly increased
deuterium uptake in oxidized sample compared to the refer-
ence (Fig. 3a). Among them, three regions showing increased
flexibility are within VH domain containing oxidized Trp1
and Trp2. Two regions showing increased flexibility are with-
in VL domain containing oxidized Trp3. The deuterium up-
take curves for peptides in all five regions show faster deuteri-
um exchange for oxidized mAb4 (Fig. 3b). No other domains
of mAb4 showed a significant difference in deuterium uptake,
similar to the findings in mAb1.
HDX-MS results also revealed Trp oxidation increased
flexibility in nearby regions to different extents for mAb1
and mAb4. Oxidation of Trp1 in CDR2 of HC of mAb1
increased flexibility of the region covering both CDR2 and
CDR1 of HC (23–36 and 50–68). This is not surprising since
the homology model for an IgG1 Fab (PDB 1HZH) indicates
these two regions are in proximity of each other in the 3-D
structure (Fig. 4a). Modifications such as adding two oxygen
atoms to the side chain of Trp1 (shown as black sticks in Fig.
4a) will increase spatial occupancy and decrease the hydro-
phobicity of the Trp side chain. This chemical change to Trp1
not only destabilizes CDR2 of HC, but also destabilizes
CDR1 of HC. Conceptually, CDR3 of HC is likely to be
affected too, since it is in proximity of both conformationally
perturbed regions. Unfortunately, it is in an area of missing
coverage, thus no experimental evidence was obtained (Fig.
S2). In addition, CDR1 and CDR3 of LC are in areas of
missing coverage, but their conformation could be impacted
by the Trp1 oxidation too.
For mAb4, the three oxidized Trp residues (Trp1, Trp2,
and Trp3) are located in CDR3 of HC, variable region of
HC, and CDR3 of LC, respectively. HDX-MS data show
increased flexibility in regions dispersed across variable re-
gions of heavy chain and light chains (VH and VL). The
homologymodel for an IgG4 Fab (PDB 5DK3) indicates these
regions are close to the Trp oxidation sites (Fig. 4b). Region
11–33 spans CDR1 of HC, with the N-terminus close to Trp2
and C-terminus close to both Trp1 and Trp3. Region 48–78
spans CDR2 of HC, near destabilized region 11–33, and is
close to both Trp1 and Trp3. Region 110–123 of HC is near
Trp2 with the N-terminus close to CDR3 of HC containing
Trp1. N-terminus of region 1–11 of LC is near Trp3. Region
47–70 spans CDR2 of LC and is near Trp1 and destabilized
region 110–123 on HC. All the VH and VL regions with
increased flexibility upon Trp oxidation are either in proxim-
ity of oxidation site(s) or in proximity of other destabilized
regions. Oxidized Trp1 and Trp3 of CDR3 of HC and LC,
respectively, are in proximity of conformationally perturbed
regions of HC (11–33 and 48–78) and LC (1–11 and 47–70).
The pattern of conformational destabilization suggests that
the CDR3 region conformations are also impacted by oxida-
tion of Trp1 or Trp3. However, since they are in an area of
missing coverage, no experimental evidence could be obtain-
ed (Fig. S3). Also, the N-terminus of HC that contains
Table I mAb1 Percent Oxidation
Measured by Tryptic Peptide
Mapping
Trp1 (CDR2 HC) Met1 (CDR3 HC) Met2 (Fc) Met3 (Fc) Met4 (Fc)
Reference 0.2 0.8 1.6 0.8 0.4
AAPH Oxidized 86.7 14.5 3.0 1.2 0.4
Table II mAb4 Percent Oxidation
Measured by Tryptic Peptide
Mapping
Trp1 (CDR3 HC) Trp2 (VH) Trp3 (CDR3 LC) Met1 (Fc) Met2 (Fc) Met3 (Fc)
Reference 1.4 1.0 3.9 4.3 2.0 3.4
AAPH Oxidized 99.9 85.9 99.8 8.3 1.8 5.8
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oxidized Trp2 is in an area of missing coverage.
Conformation in this region is likely to be impacted as well
due to destabilized neighboring regions of HC (11–33 and
110–123).
Comparing HDX-MS results of mAb4 to mAb1, the for-
mer shows a more dispersed increase of flexibility across both
VH and VL. This is not surprising considering there are three
Trp oxidation sites in the two domains of mAb4 vs only one in
mAb1. This data demonstrates Trp oxidation destabilized
nearby regions and caused increasing flexibility in protein
conformation. The treatment by AAPH and excess free Met
provided the analytical probe to uncover the conformational
impact of Trp oxidation. Minimal Met oxidation along with
the absence of other modifications were essential in maintain-
ing the selectivity of the study that was focused on Trp oxida-
tion, as other modifications may have structural and/or func-
tional impact on mAbs as well. For example, Met oxidation in
Fc region of mAbs may cause conformational changes in the
CH2 domain, contributing to an aggregation hotspot in region
FLFPPKPKDTLM (36). Minimizing Met oxidation during
AAPH treatment allowed us to avoid such changes and probe
the impact of Trp oxidation alone. The fact that deuterium
uptake curves show little difference between oxidized and ref-
erence samples in the above mentioned region for mAb1 (HC
249–259) and for mAb4 (HC 242–253) further demonstrates
the selectivity of AAPH treatment for Trp oxidation with
minimal Met oxidation.
The HDX-MS results highlight the conformational
impact of Trp oxidation on VH and VL of mAb1 and
mAb4. Most of the Trp residues are buried in hydro-
phobic cores and are not susceptible to oxidation.
However, Trp provides unique touch points for
protein-protein interactions hence they are frequently
found in the CDRs of mAbs. Trp residues in CDRs
not only play important roles in antigen binding, but
also in maintaining conformational stability of CDRs.
CDRs carry conformational flexibility, which contributes
to their functionality as paratopes for antigen binding.
With underlying flexibility and exposure, Trp in CDRs
are unable to pack tightly as they would in a hydropho-
bic core. Even with the lack of packing for Trps in the
CDRs, their oxidation disrupts native conformation of
VH and VL. Such destabilization can alter CDR’s func-
tionality and impact long term stability.
SPR Results Indicate Disrupted Antigen Binding
Caused by Trp Oxidation in CDRs
SPR by Biacore was used to characterize the impact of
Trp oxidation on antigen binding for mAb1 and mAb4.
Kinetic association and dissociation rates of antigen with
mAb were measured by SPR. Capture of reference
mAbs and oxidized mAbs were compared and shown
to be similar (see Fig. S6), which indicates structural
perturbations by oxidation in variable domains did not
disrupt the capture of oxidized mAb by anti-Fab for
SPR analysis.
Taking a window of response at an equilibrium binding
point for each antigen concentration respective to each mAb
allowed us to plot response versus antigen concentration (see
Fig. S7 and Fig. S8). At binding equilibrium of the highest
antigen concentration (40 nM), oxidized mAb1 showed
19.4% relative antigen binding compared to reference stan-
dard, as calculated by taking a ratio of the response for the
oxidized material to the response for the reference standard
(Fig. 5a). These results show oxidation of Trp1 in CDR2 of
HC disrupts antigen binding for mAb1. Kinetic constants for
oxidizedmAb1 cannot be reliably calculated due to the lack of
antigen binding response. Kinetic constants for reference
mAb1 are in the expected range from previous development
measurements (see Table S1). Each of the concentrations was
Fig. 1 Overlaid SEC chromatograms detected at 220 nm of (a) Reference
material and oxidized mAb1, (b) Reference material and oxidized mAb4, (c)
Oxidized mAb4 prior to and post (enriched) fraction collection.
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injected in triplicate; the error associated with the binding
equilibrium at the highest antigen concentration for mAb1 is
±5.7%. Considering there is approximately 15% of unmodi-
fiedmAb1 in the oxidized sample (Table I), the 19.4% relative
percent antigen binding was likely contributed by the unmod-
ified molecules.
At binding equilibrium of the highest antigen concen-
tration (40 nM), oxidized mAb4 showed 6.1% relative
antigen binding compared to reference standard (Fig.
5b). These results show oxidation of Trp1 in CDR3 of
HC, Trp2 in VH, and Trp3 in CDR3 of LC signifi-
cantly disrupt mAb interaction with antigen. Again, the
kinetic constants for oxidized mAb4 cannot be reliably
calculated due to the lack of antigen binding response.
Kinetics for mAb4 reference standard are in the expect-
ed range from previous development measurements (see
Table S1). The error associated with the binding equi-
librium at the highest antigen concentration for mAb4 is
±6.0%.
The disrupted antigen binding for mAb1 can be ex-
plained by the local conformational perturbation
exerted by Trp oxidation which increased the flexibility
of CDR2 of HC and CDR1 of HC. Also, it is impor-
tant to consider the chemical change associated with
Trp oxidation. Addition of two oxygen atoms to a
Trp side chain drastically changes the nature of a Trp
side chain, which consequently changes the native
chemical properties of Trp. If Trp is a strong contact
point in the antigen-antibody interface, then a combina-
tion of increased flexibility across two CDRs of the HC
and the associated chemical change in Trp severely
disrupted antigen-mAb1 interaction.
Fig. 2 mAb1HDX-MS (a) Summed deuterium uptake differences across 5 exposure times for each peptide. Peptides are arranged on the horizontal axis starting
from the N-terminal end of the HC and ending at the C-terminal end of the LC. Bottom plot labels indicate peptide domain locations. The vertical axis is the
difference of deuterium uptake between oxidized and reference material. Individual deuterium uptake differences (ΔDt= # Dt, Oxidized – # Dt, Reference) are
represented as lines: 20 s (gold), 100 s (red), 500 s (cyan), 2500 s (blue), and 12,500 s (black). Summed differences (∑ΔDt) are represented as grey bars for each
peptide. The dashed lines at ±0.9 Da are the 98% confidence limits for significant summed differences (see Fig. S4). (b) Peptide deuterium uptake curves
representative of regions labeled in panel a. HDX was corrected for Trp oxidation containing peptides (see Fig. S5). 3 × SD error bars for each triplicate
measurement are displayed.
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Fig. 3 mAb4HDX-MS (a) Summed deuterium uptake differences across 5 exposure times for each peptide. Peptides are arranged on the horizontal axis starting
from the N-terminal end of the HC and ending at the C-terminal end of the LC. Bottom plot labels indicate peptide domain locations. The vertical axis is the
difference of deuterium uptake between oxidized and reference material. Individual deuterium uptake differences (ΔDt= # Dt, Oxidized – # Dt, Reference) are
represented as lines: 20 s (gold), 100 s (red), 500 s (cyan), 2500 s (blue), and 12,500 s (black). Summed differences (∑ΔDt) are represented as grey bars for each
peptide. The dashed lines at ±0.9 Da are the 98% confidence limits for significant summed differences (see Fig. S4). (b) Peptide deuterium uptake curves
representative of regions labeled in panel a. 3 × SD error bars for each triplicate measurement are displayed.
Fig. 4 Significant differences in
deuterium uptake mapped onto
homology structure of Fab. HC
(grey), LC (wheat), oxidized Trp
(black), and increased HDX (red).
(a) mAb1 (PDB 1HZH) mapped
increased HDX of oxidized in
labeled regions of HC: 23–36 and
50–68. (b) mAb4 (PDB 5DK3)
mapped increased HDX of oxi-
dized in labeled regions of HC: 11–
33, 48–78 and 110–123; LC: 1–11
and 47–70.
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Similarly, the disrupted antigen binding for mAb4 can be
explained by the dispersed conformational perturbations from
Trp oxidation, which increased flexibility across both VH and
VL. With two Trp residues lying within the CDRs near each
other and four oxygen atoms added in that space, the chem-
ical environment changes significantly. The impact on antigen
binding caused by Trp oxidation with the associated structural
perturbations (increased flexibility) and chemical changes are
similar for mAb1 and mAb4.
CONCLUSION
AAPH treatment in the presence of excess free Met is a suit-
able approach to selectively oxidize Trp for site specific deg-
radation studies, such as structure-function relationship stud-
ies concerning Trp oxidation. Oxidation of Trp in CDRs of
mAbs significantly disrupts antigen binding as shown for the
IgG1 and IgG4 mAbs used in this study. Oxidation of Trp in
CDRs of mAbs alters conformation in variable domains to
different extents as shown in mAb1 and mAb4. Chemical
modification brought by Trp oxidation can lead to undesir-
able physical changes in mAbs such as increased propensity
for aggregation and loss of potency. The increased flexibility
in the CDRs containing oxidized Trp resulted in the loss of
antigen binding activity for the studied IgG1 and IgG4 mAbs,
which is also highly applicable to other mAbs containing
CDRs with Trp residues. Additional studies can be performed
to further explore the correlation between increased flexibility
with protein stability, which could be a long term impact
stemming from Trp oxidation. In conclusion, this study pro-
vides a highly effective tool for understanding the structure
function relationships for CDR Trp oxidation without the
interference from other degradations. CDR Trp oxidation
should be carefully monitored during process development
of mAbs. If susceptible Trp residues are found at an impactful
rate in well-controlled products, it should be considered in
critical quality attribute assessments in which a comprehensive
understanding of degradation pathways and impact on prod-
uct quality are essential in order to establish appropriate con-
trol strategies for therapeutic proteins.
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